{"name":"Nanjing Zenshine Pharmaceuticals","slug":"nanjing-zenshine-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ZX-7101A for oral suspension","genericName":"ZX-7101A for oral suspension","slug":"zx-7101a-for-oral-suspension","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ZX-7101A dry suspension","genericName":"ZX-7101A dry suspension","slug":"zx-7101a-dry-suspension","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ZX-7101A for oral suspension","genericName":"ZX-7101A for oral suspension","slug":"zx-7101a-for-oral-suspension","phase":"phase_3","mechanism":"ZX-7101A is a small molecule that targets the HIF-1α pathway.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"ZX-7101A dry suspension","genericName":"ZX-7101A dry suspension","slug":"zx-7101a-dry-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1rSWVXSUhzU0JpWVpiYVZ4cG5LTEpfZ0E1WER4aU9SR0NIcmZPUkJfd3IyOGF5X09TTG81b3diR1pqWFJEM09kQ1hyTEhSR3JwTXFrLUd1a1ZjX2pRQV9TNDBISmpGdl9SZTJKVUdwOTJyU0tfaks1VA?oc=5","date":"2023-04-14","type":"trial","source":"Clinical Trials Arena","summary":"Zenshine’s Phase ll influenza therapy trial meets primary endpoint - Clinical Trials Arena","headline":"Zenshine’s Phase ll influenza therapy trial meets primary endpoint","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}